The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
Amgen Inc (NASDAQ:AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna ...
Uplizna also hit the target on a number of secondary measures, including: annualised flare rate; flare-free, treatment-free ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
The FDA's vaccine advisory panel voted to recommend that this fall’s Covid-19 shots should be updated to target Omicron’s ...
Interestingly, Bkemv is the 53rd approved biosimilar in the U.S. The FDA has approved 13 of these as interchangeable ...
The world's first human trial of a drug designed to regenerate real teeth is set to commence in jus… ...
So far only three GLP-1 drugs have been approved to treat obese or overweight individuals: liraglutide and semaglutide, ...
The facility, which will be the drugmaker's first end-to-end ADC production site, will be supported by the Singapore Economic Development Board. The company did not provide details on the possible ...
ASCO Annual Meeting kicks off today, showcasing the latest research in cancer therapies to scientists and physicians.